FY2025 EPS Estimates for Rallybio Lifted by HC Wainwright

Rallybio Co. (NASDAQ:RLYB) – Research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Rallybio in a report released on Monday, March 17th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($1.20) per share for the year, up from their previous forecast of ($1.22). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Rallybio’s current full-year earnings is ($1.34) per share.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.15 million.

Rallybio Trading Up 14.4 %

Shares of Rallybio stock opened at $0.73 on Wednesday. The business’s 50 day simple moving average is $0.80 and its 200-day simple moving average is $0.97. The stock has a market capitalization of $30.47 million, a price-to-earnings ratio of -0.46 and a beta of -1.45. Rallybio has a twelve month low of $0.62 and a twelve month high of $3.46.

Institutional Trading of Rallybio

Large investors have recently added to or reduced their stakes in the business. Northeast Financial Consultants Inc increased its position in Rallybio by 336.5% in the 4th quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock valued at $93,000 after acquiring an additional 74,334 shares during the period. Geode Capital Management LLC increased its position in Rallybio by 11.4% in the 3rd quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock valued at $287,000 after acquiring an additional 24,980 shares during the period. Renaissance Technologies LLC increased its position in Rallybio by 9.3% in the 4th quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock valued at $424,000 after acquiring an additional 37,618 shares during the period. Allostery Investments LP acquired a new stake in Rallybio in the 4th quarter valued at approximately $771,000. Finally, Almitas Capital LLC increased its position in Rallybio by 48.3% in the 4th quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock valued at $1,246,000 after acquiring an additional 422,685 shares during the period. 90.34% of the stock is currently owned by institutional investors and hedge funds.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.